Healthcare · Biotechnology · NASDAQ
| Market cap | $4.53B |
|---|---|
| Trailing P/E | — |
| Price / book | 11.5 |
| Price / sales | 4.7 |
| FCF yield | -7.5% |
| Dividend yield | — |
| Gross margin | 98.2% |
| Operating margin | -58.8% |
| Net margin | -56.9% |
| Revenue growth (YoY) | +33.8% |
| Revenue growth (3-yr annual) | +17.1% |
| EPS growth (YoY) | — |
| FCF/share growth (YoY) | — |
| Beta | 0.4 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.93). Beat the EPS estimate in 4 of 4 recent quarters.
| Quarter | Reported | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3 2026 | Nov 9, 2026 | -$0.40 | -$0.93 | +57.0% | $242.72M |
| Q2 2026 | Jul 29, 2026 | -$0.42 | -$0.88 | +52.3% | $267.95M |
| Q1 2026 | Apr 29, 2026 | -$0.30 | -$0.77 | +61.0% | $246.09M |
| Q4 2025 | Feb 25, 2026 | -$1.15 | -$1.22 | +5.7% | $203.33M |
Median target $68.00 from 23 analysts, ranging $41.00 – $105.00.
| Ticker | Company | Market cap | P/E |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $132.01B | 27.4 |
| REGN | Regeneron Pharmaceuticals | $95.52B | 16.7 |
| MRNA | Moderna | $80.65B | — |
| ARGX | argenx | $59.24B | 32.9 |
| ONC | BeOne Medicines | $45.66B | 50.8 |
| RPRX | Royalty Pharma | $38.94B | 12.8 |
| RVMD | Revolution Medicines | $34.48B | — |
| INSM | Insmed | $31.69B | — |
Ionis Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Sheldon Whitehouse | Senate | Sell | $1,001 - $15,000 | — |